XZP-7797 / Sihuan Pharmaceutical - LARVOL DELTA

Discovery of a potent, selective and brain penetrating PARP1 inhibitor, XZP-7797 (AACR 2024) - "Additionally, XZP-7797 has great PK profiles in preclinical species after oral dosing and good ADME properties. In a 14-day toxicology study of XZP-7797 in SD Rats, XZP-7797 has no hematological adverse effects at the exposure that is 10 times higher than the exposure required to achieve superior efficacy."

Late-breaking abstract • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HRD • PARP2 • PARP3 • TNKS2